Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
What hotspot and heterogeneity metrics do you utilize when delivering PMRT to a patient who has had breast reconstruction?
How do you use 105%, 107% and max dose metrics differently compared with non-reconstructed cases?
Answer from: Radiation Oncologist at Academic Institution
I try to follow the same as intact breast. Limiting hot spot < 110 and V 105 < 5-10% and not hot spot in IM fold. Patel et al., PMID 30145393
Sign in or Register to read more
22655
Related Questions
What are your thoughts on the relevance of sentinel lymph node biopsy before the onset of neoadjuvant chemotherapy for HER2+ or triple negative cT2+N0M0 breast cancer patients?
In a patient with cardiac comorbidities, who meets ASTRO APBI criteria other than a positive margin, would you offer APBI in an attempt to reduce cardiac dose?
What are the current indications for proton beam therapy in the treatment of breast cancer?
How would you approach a patient that did not have preoperative axillary imaging and was found to have macromets on sentinel node biopsy, and on radiation planning scan has abnormal appearing nodes?
Would you cover regional nodes in an early-stage breast cancer with a non-mapping sentinel lymph node?
Would you offer breast conserving therapy in a patient with breast cancer and Buerger's disease of the breast?
What is the current paradigm for breast cancer diagnosed with isolated metastases prior to initial treatment?
Do you ever treat a recurrent breast cancer with RNI alone rather than chest wall and RNI?
Is it acceptable to give hypofractionated breast radiation in a patient who is being treated for rheumatoid arthritis with Actemra, methotrexate and leucovorin?
Do you recommend re-excision of a unifocal positive anterior margin at skin after lumpectomy in a patient with otherwise low risk breast cancer features?